Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.93 SEK | +5.40% | +1.38% | -61.75% |
27/06 | Transcript : Oncopeptides AB - Special Call | |
30/05 | Oncopeptides Issues Warrants Under Loan Deal with European Investment Bank | MT |
Sales 2024 * | 84.16M 7.94M 662M | Sales 2025 * | 199M 18.79M 1.57B | Capitalization | 630M 59.5M 4.96B |
---|---|---|---|---|---|
Net income 2024 * | -241M -22.75M -1.9B | Net income 2025 * | -172M -16.23M -1.35B | EV / Sales 2024 * | 4.94 x |
Net cash position 2024 * | 215M 20.28M 1.69B | Net cash position 2025 * | 71.92M 6.79M 566M | EV / Sales 2025 * | 2.81 x |
P/E ratio 2024 * |
-1.44
x | P/E ratio 2025 * |
-2.71
x | Employees | 62 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.53% |
Latest transcript on Oncopeptides AB
1 day | +5.40% | ||
1 week | +1.38% | ||
Current month | -8.44% | ||
1 month | +2.81% | ||
3 months | -54.92% | ||
6 months | -61.50% | ||
Current year | -61.75% |
Managers | Title | Age | Since |
---|---|---|---|
Sofia Heigis
CEO | Chief Executive Officer | 44 | 01/20/01 |
Director of Finance/CFO | 50 | 13/11 | |
Eva Nordström
COO | Chief Operating Officer | 54 | 01/12/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Per Wold-Olsen
CHM | Chairman | 76 | 17/18/17 |
Director/Board Member | 63 | 01/12/01 | |
Director/Board Member | 61 | 01/17/01 |
Date | Price | Change | Volume |
---|---|---|---|
28/24/28 | 2.93 | +5.40% | 2,854,608 |
27/24/27 | 2.78 | 0.00% | 1,095,031 |
26/24/26 | 2.78 | -0.54% | 669,451 |
25/24/25 | 2.795 | -4.61% | 1,047,168 |
24/24/24 | 2.93 | +1.38% | 849,373 |
Delayed Quote Nasdaq Stockholm, June 28, 2024 at 09:30 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-61.75% | 59.49M | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- ONCO Stock